Huiyuan Tang
Papers
1
Total Citations
45
H-Index
1
About
Huiyuan Tang is a leading figure in cancer glycobiology, whose work has reshaped our understanding of glycan-based biomarkers for early disease detection. Her research centers on the role of aberrant glycosylation in pancreatic cancer, with a particular focus on the limitations and hidden opportunities within the CA19-9 assay—the current gold-standard biomarker. In her seminal 2015 study, Tang challenged the clinical blind spot of sialyl-Lewis A (sLeA)-negative tumors, which account for roughly 25% of pancreatic cancers and are missed by standard tests. By employing advanced glycan motif profiling, she demonstrated that these sLeA-low tumors instead secrete elevated levels of sialyl-Lewis X (sLeX), a related glycan structure. This discovery not only identified a novel plasma biomarker for a previously undetectable patient subset but also opened a new avenue for improving diagnostic sensitivity. With 45 citations, this work has become a cornerstone for researchers seeking to expand the glycan-based diagnostic toolkit. Tang’s contributions are pivotal for students and scientists aiming to bridge the gap between fundamental glycobiology and clinical oncology, offering a clear path toward more inclusive cancer screening.
Research Focus
Key Achievements
Top Papers
- 1